BioCentury
ARTICLE | Company News

Amgen beats Street, again raises 2016 guidance

April 29, 2016 1:58 AM UTC

On Thursday, Amgen Inc. (NASDAQ:AMGN) reported 1Q16 financial results that beat estimates and raised its 2016 EPS and revenue guidances yet again. Revenues in the quarter were $5.5 billion, up from $5 billion in 1Q15 and beating the $5.3 billion analysts were expecting. Adjusted diluted EPS were $2.90, up from $2.48 in 1Q15 and topping the Street's $2.60 estimate.

Worldwide sales of PCSK9 inhibitor Repatha evolocumab were $16 million in 1Q16, with $14 million coming from the U.S. Amgen has not previously broken out its sales of the drug, which it launched in early September in the U.S. and Europe. ...